IDeAYA Biosciences weekly recap highlights darovasertib NDA progress
The recap says darovasertib is nearing NDA submission as multiple Phase III trials advance, alongside pipeline momentum from a DLL3 ADC and MTAP/KRAS programs.
The recap says darovasertib is nearing NDA submission as multiple Phase III trials advance, alongside pipeline momentum from a DLL3 ADC and MTAP/KRAS programs.